7 results
8-K
EX-99.1
INVA
Innoviva Inc
13 May 24
Corporate Presentation May 2024
9:27am
Royalty Assets 5 Our royalty assets, composed of widely used respiratory therapies commercialized by GSK, have produced durable, resilient revenues … driven by resilient cash flows from our core GSK royalties portfolio and robust revenue growth across our commercial products marketed by IST
8-K
EX-99.1
INVA
Innoviva Inc
8 May 24
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
4:44pm
financial results continue to demonstrate the successful transformation for Innoviva. We had a strong performance driven by resilient cash flows from
8-K
EX-99.1
INVA
Innoviva Inc
24 May 23
Corporate Presentation May 2023
5:18pm
, composed of widely used respiratory therapies commercialized by GSK, have produced durable, resilient revenues that are de - risked via geographic and drug
8-K
EX-99.1
INVA
Innoviva Inc
14 Sep 22
Regulation FD Disclosure
5:22pm
Sizeable and differentiated Resilient anddurable Diversifiedand established Differentiated respiratory portfolio with over $2B 2021 sales (for Breo and Anoro
8-K
EX-99.1
x9k5vk4
7 Apr 22
Regulation FD Disclosure
5:09pm
8-K
EX-99.1
031u4r2pcvuj3
13 Dec 21
Corporate Presentation December 2021
4:39pm
- Prev
- 1
- Next